Last mentioned: 2d ago
Second ATA Victory
Binance secures its second major dismissal under the Anti-Terrorism Act in two weeks.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
First ATA Victory
U.S. court dismisses the first major ATA lawsuit against Binance, citing lack of proximate cause.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
DOJ Settlement
Binance reaches a $4.3 billion settlement with the DOJ and CFTC over AML and KYC failures.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
A federal judge has halted the enforcement of subpoenas directed at the Federal Reserve as part of a criminal investigation involving Chair Jerome Powell. The ruling has drawn sharp criticism from legal analysts and introduces significant leadership uncertainty for the central bank.
Binance has successfully defended against a second major lawsuit under the U.S. Anti-Terrorism Act, marking a significant legal winning streak for the crypto giant. These rulings reinforce the high evidentiary bar required to hold digital asset exchanges liable for the actions of third-party bad actors.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.